Schedule of Investments(a)
Invesco Nasdaq Biotechnology ETF (IBBQ)
November 30, 2023
(Unaudited)
| Shares | Value | |||
| Common Stocks & Other Equity Interests-99.97% | ||||
| Biotechnology-83.65% | ||||
2seventy bio, Inc.(b)(c) | 851 | $1,557 | ||
4D Molecular Therapeutics, Inc.(b)(c) | 730 | 9,286 | ||
89bio, Inc.(b)(c) | 1,327 | 10,669 | ||
Abcam PLC, ADR (United Kingdom)(b) | 3,749 | 89,864 | ||
Absci Corp.(b)(c) | 1,563 | 2,610 | ||
Acadia Pharmaceuticals, Inc.(b)(c) | 2,861 | 63,743 | ||
Acumen Pharmaceuticals, Inc.(b) | 975 | 2,340 | ||
Adaptimmune Therapeutics PLC, ADR(b) | 3,472 | 1,736 | ||
Adicet Bio, Inc.(b) | 726 | 857 | ||
ADMA Biologics, Inc.(b) | 3,938 | 14,571 | ||
Affimed N.V. (Germany)(b) | 2,517 | 1,133 | ||
Agios Pharmaceuticals, Inc.(b)(c) | 973 | 21,630 | ||
Akero Therapeutics, Inc.(b) | 975 | 16,321 | ||
Alaunos Therapeutics, Inc.(b) | 4,055 | 268 | ||
Alector, Inc.(b)(c) | 1,478 | 8,011 | ||
Alkermes PLC(b) | 2,909 | 70,223 | ||
Allakos, Inc.(b)(c) | 1,561 | 3,465 | ||
Allogene Therapeutics, Inc.(b)(c) | 2,911 | 6,841 | ||
Allovir, Inc.(b) | 2,040 | 3,835 | ||
Alnylam Pharmaceuticals, Inc.(b)(c) | 2,183 | 367,290 | ||
Alpine Immune Sciences, Inc.(b)(c) | 1,014 | 15,717 | ||
Altimmune, Inc.(b) | 888 | 2,806 | ||
ALX Oncology Holdings, Inc.(b) | 841 | 6,593 | ||
Amarin Corp. PLC, ADR (Ireland)(b) | 6,789 | 5,309 | ||
Amgen, Inc. | 5,604 | 1,511,063 | ||
Amicus Therapeutics, Inc.(b)(c) | 5,015 | 55,265 | ||
AnaptysBio, Inc.(b)(c) | 462 | 6,533 | ||
Anavex Life Sciences Corp.(b)(c) | 1,444 | 10,411 | ||
Annexon, Inc.(b) | 897 | 2,234 | ||
Apellis Pharmaceuticals, Inc.(b)(c) | 2,058 | 110,864 | ||
Arbutus Biopharma Corp.(b) | 2,956 | 6,060 | ||
Arcellx, Inc.(b)(c) | 845 | 44,388 | ||
Arcturus Therapeutics Holdings, Inc.(b)(c) | 468 | 11,204 | ||
Arcutis Biotherapeutics, Inc.(b)(c) | 1,614 | 2,970 | ||
Ardelyx, Inc.(b)(c) | 3,796 | 17,120 | ||
Argenx SE, ADR (Netherlands)(b) | 520 | 234,317 | ||
Arrowhead Pharmaceuticals, Inc.(b)(c) | 1,872 | 39,686 | ||
ARS Pharmaceuticals, Inc.(b)(c) | 1,656 | 7,998 | ||
Ascendis Pharma A/S, ADR (Denmark)(b) | 997 | 100,129 | ||
Atara Biotherapeutics, Inc.(b) | 1,704 | 1,125 | ||
Aurinia Pharmaceuticals, Inc. (Canada)(b) | 2,502 | 21,617 | ||
Avidity Biosciences, Inc.(b)(c) | 1,306 | 10,200 | ||
Beam Therapeutics, Inc.(b)(c) | 1,383 | 38,835 | ||
BeiGene Ltd., ADR (China)(b)(c) | 735 | 137,401 | ||
Bicycle Therapeutics PLC, ADR (United Kingdom)(b)(c) | 465 | 6,696 | ||
BioAtla, Inc.(b)(c) | 806 | 1,427 | ||
BioCryst Pharmaceuticals, Inc.(b)(c) | 3,303 | 19,422 | ||
Biogen, Inc.(b) | 2,530 | 592,222 | ||
BioMarin Pharmaceutical, Inc.(b) | 3,289 | 299,562 | ||
Biomea Fusion, Inc.(b)(c) | 628 | 9,464 | ||
BioNTech SE, ADR (Germany)(b)(c) | 1,634 | 164,070 | ||
Bluebird Bio, Inc.(b)(c) | 1,887 | 7,208 | ||
Blueprint Medicines Corp.(b) | 1,060 | 73,818 | ||
Bridgebio Pharma, Inc.(b) | 2,841 | 81,565 | ||
C4 Therapeutics, Inc.(b)(c) | 829 | 1,351 | ||
Caribou Biosciences, Inc.(b)(c) | 1,560 | 9,157 | ||
Cartesian Therapeutics, Inc.(b)(c) | 2,633 | 3,555 | ||
Centessa Pharmaceuticals PLC, ADR(b)(c) | 933 | 5,598 | ||
Century Therapeutics, Inc.(b) | 1,007 | 1,380 | ||
Cogent Biosciences, Inc.(b) | 1,501 | 11,513 | ||
| Shares | Value | |||
| Biotechnology-(continued) | ||||
Coherus Biosciences, Inc.(b) | 1,908 | $4,064 | ||
Compass Pathways PLC, ADR (United Kingdom)(b)(c) | 461 | 2,757 | ||
Crinetics Pharmaceuticals, Inc.(b)(c) | 1,156 | 36,749 | ||
CRISPR Therapeutics AG (Switzerland)(b)(c) | 1,387 | 92,555 | ||
Cullinan Oncology, Inc.(b) | 751 | 6,151 | ||
CureVac N.V. (Germany)(b)(c) | 3,908 | 21,103 | ||
Cytokinetics, Inc.(b)(c) | 1,678 | 56,179 | ||
Day One Biopharmaceuticals, Inc.(b)(c) | 1,524 | 17,648 | ||
Deciphera Pharmaceuticals, Inc.(b) | 1,373 | 17,314 | ||
Denali Therapeutics, Inc.(b)(c) | 2,404 | 44,522 | ||
Design Therapeutics, Inc.(b) | 944 | 2,266 | ||
Dyne Therapeutics, Inc.(b)(c) | 1,060 | 11,745 | ||
Eagle Pharmaceuticals, Inc.(b) | 227 | 1,328 | ||
Editas Medicine, Inc.(b)(c) | 1,430 | 15,058 | ||
Eiger BioPharmaceuticals, Inc.(b) | 747 | 254 | ||
Enanta Pharmaceuticals, Inc.(b)(c) | 376 | 3,512 | ||
Erasca, Inc.(b)(c) | 2,619 | 4,452 | ||
Evelo Biosciences, Inc.(b) | 310 | 124 | ||
Exelixis, Inc.(b) | 5,564 | 121,351 | ||
Exscientia PLC, ADR (United Kingdom)(b)(c) | 787 | 4,801 | ||
Fate Therapeutics, Inc.(b) | 1,739 | 4,330 | ||
FibroGen, Inc.(b)(c) | 1,655 | 914 | ||
Foghorn Therapeutics, Inc.(b)(c) | 706 | 3,000 | ||
G1 Therapeutics, Inc.(b)(c) | 872 | 1,639 | ||
Galapagos N.V., ADR (Belgium)(b) | 343 | 12,838 | ||
Generation Bio Co.(b) | 1,111 | 1,255 | ||
Genmab A/S, ADR (Denmark)(b) | 735 | 23,233 | ||
Geron Corp.(b) | 9,182 | 17,721 | ||
Gilead Sciences, Inc. | 18,784 | 1,438,854 | ||
Gossamer Bio., Inc.(b) | 3,797 | 2,970 | ||
Gracell Biotechnologies, Inc., ADR (China)(b)(c) | 1,194 | 5,815 | ||
Graphite Bio, Inc.(b) | 977 | 2,218 | ||
Grifols S.A., ADR (Spain)(b) | 2,124 | 20,582 | ||
Gritstone bio, Inc.(b) | 1,597 | 2,076 | ||
Halozyme Therapeutics, Inc.(b)(c) | 2,305 | 88,996 | ||
HilleVax, Inc.(b)(c) | 821 | 11,256 | ||
Humacyte, Inc.(b) | 1,834 | 4,860 | ||
Ideaya Biosciences, Inc.(b)(c) | 1,124 | 35,350 | ||
IGM Biosciences, Inc.(b)(c) | 588 | 3,963 | ||
I-Mab, ADR (China)(b) | 1,176 | 1,835 | ||
Immuneering Corp., Class A(b)(c) | 526 | 3,451 | ||
ImmunityBio, Inc.(b)(c) | 11,672 | 42,953 | ||
Immunocore Holdings PLC, ADR (United Kingdom)(b)(c) | 572 | 30,162 | ||
ImmunoGen, Inc.(b)(c) | 4,351 | 127,702 | ||
Immunovant, Inc.(b)(c) | 2,529 | 98,960 | ||
Incyte Corp.(b) | 3,916 | 212,795 | ||
Inhibrx, Inc.(b)(c) | 762 | 15,827 | ||
Inovio Pharmaceuticals, Inc.(b)(c) | 4,518 | 1,781 | ||
Insmed, Inc.(b)(c) | 2,513 | 62,875 | ||
Instil Bio, Inc.(b) | 2,192 | 743 | ||
Intellia Therapeutics, Inc.(b)(c) | 1,545 | 45,778 | ||
Invivyd, Inc.(b) | 1,884 | 2,883 | ||
Ionis Pharmaceuticals, Inc.(b)(c) | 2,505 | 123,922 | ||
Iovance Biotherapeutics, Inc.(b) | 4,342 | 26,356 | ||
Ironwood Pharmaceuticals, Inc.(b) | 2,729 | 27,017 | ||
iTeos Therapeutics, Inc.(b) | 633 | 5,925 | ||
Karuna Therapeutics, Inc.(b)(c) | 658 | 125,816 | ||
Karyopharm Therapeutics, Inc.(b) | 1,927 | 1,484 | ||
Keros Therapeutics, Inc.(b)(c) | 516 | 15,655 | ||
Kezar Life Sciences, Inc.(b) | 1,225 | 1,026 | ||
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
November 30, 2023
(Unaudited)
| Shares | Value | |||
| Biotechnology-(continued) | ||||
Kiniksa Pharmaceuticals Ltd., Class A(b)(c) | 613 | $9,912 | ||
Kinnate Biopharma, Inc.(b) | 794 | 1,802 | ||
Kodiak Sciences, Inc.(b) | 884 | 2,139 | ||
Krystal Biotech, Inc.(b)(c) | 489 | 50,968 | ||
Kura Oncology, Inc.(b)(c) | 1,303 | 12,600 | ||
Kymera Therapeutics, Inc.(b)(c) | 972 | 20,179 | ||
Legend Biotech Corp., ADR(b)(c) | 1,393 | 84,722 | ||
Lexicon Pharmaceuticals, Inc.(b)(c) | 4,280 | 4,537 | ||
Lyell Immunopharma, Inc.(b)(c) | 4,411 | 7,631 | ||
MacroGenics, Inc.(b)(c) | 1,073 | 8,809 | ||
Madrigal Pharmaceuticals, Inc.(b)(c) | 323 | 65,666 | ||
MannKind Corp.(b)(c) | 4,688 | 16,971 | ||
MeiraGTx Holdings PLC(b) | 1,031 | 5,382 | ||
Mersana Therapeutics, Inc.(b) | 2,068 | 3,412 | ||
Merus N.V. (Netherlands)(b) | 1,007 | 24,913 | ||
Mirati Therapeutics, Inc.(b)(c) | 1,193 | 67,703 | ||
Mirum Pharmaceuticals, Inc.(b)(c) | 815 | 26,137 | ||
Moderna, Inc.(b)(c) | 6,650 | 516,705 | ||
Monte Rosa Therapeutics, Inc.(b)(c) | 852 | 2,641 | ||
Morphic Holding, Inc.(b)(c) | 837 | 19,837 | ||
Mural Oncology PLC (Ireland)(b) | 290 | 1,047 | ||
Myriad Genetics, Inc.(b)(c) | 1,430 | 27,299 | ||
Neurocrine Biosciences, Inc.(b) | 1,706 | 198,903 | ||
Nkarta, Inc.(b)(c) | 827 | 2,183 | ||
Novavax, Inc.(b)(c) | 2,086 | 11,473 | ||
Nurix Therapeutics, Inc.(b)(c) | 850 | 5,287 | ||
Nuvalent, Inc., Class A(b)(c) | 994 | 64,978 | ||
Omega Therapeutics, Inc.(b) | 929 | 2,127 | ||
OmniAb Operations, Inc., Rts., expiring 11/02/2027(b)(c)(d) | 125 | 0 | ||
OmniAb Operations, Inc., Rts., expiring 11/02/2027(b)(d) | 125 | 0 | ||
PepGen, Inc.(b) | 401 | 1,965 | ||
PMV Pharmaceuticals, Inc.(b) | 860 | 1,969 | ||
Poseida Therapeutics, Inc.(b) | 1,645 | 4,392 | ||
Precigen, Inc.(b)(c) | 4,497 | 5,037 | ||
Prelude Therapeutics, Inc.(b) | 707 | 2,340 | ||
Protagonist Therapeutics, Inc.(b) | 1,010 | 18,392 | ||
Prothena Corp. PLC (Ireland)(b)(c) | 936 | 30,495 | ||
PTC Therapeutics, Inc.(b)(c) | 1,320 | 30,386 | ||
RAPT Therapeutics, Inc.(b)(c) | 606 | 8,799 | ||
Recursion Pharmaceuticals, Inc., Class A(b)(c) | 3,573 | 24,475 | ||
Regeneron Pharmaceuticals, Inc.(b) | 1,738 | 1,431,782 | ||
REGENXBIO, Inc.(b) | 767 | 14,972 | ||
Relay Therapeutics, Inc.(b)(c) | 2,140 | 16,927 | ||
Repare Therapeutics, Inc. (Canada)(b) | 746 | 3,842 | ||
Replimune Group, Inc.(b) | 1,028 | 11,493 | ||
REVOLUTION Medicines, Inc.(b)(c) | 2,951 | 68,847 | ||
Rhythm Pharmaceuticals, Inc.(b)(c) | 993 | 33,196 | ||
Rocket Pharmaceuticals, Inc.(b)(c) | 1,572 | 36,675 | ||
Roivant Sciences Ltd.(b)(c) | 13,489 | 128,955 | ||
Sage Therapeutics, Inc.(b) | 1,046 | 20,481 | ||
Sana Biotechnology, Inc.(b)(c) | 3,455 | 14,027 | ||
Sangamo Therapeutics, Inc.(b) | 2,985 | 1,284 | ||
Sarepta Therapeutics, Inc.(b)(c) | 1,631 | 132,568 | ||
Scholar Rock Holding Corp.(b)(c) | 1,203 | 15,146 | ||
Seagen, Inc.(b)(c) | 3,279 | 699,116 | ||
Seres Therapeutics, Inc.(b)(c) | 2,161 | 2,247 | ||
SpringWorks Therapeutics, Inc.(b)(c) | 1,094 | 33,247 | ||
Stoke Therapeutics, Inc.(b)(c) | 791 | 2,998 | ||
Summit Therapeutics, Inc.(b) | 12,175 | 24,715 | ||
Sutro Biopharma, Inc.(b) | 1,039 | 2,712 | ||
| Shares | Value | |||
| Biotechnology-(continued) | ||||
Syndax Pharmaceuticals, Inc.(b)(c) | 1,212 | $20,174 | ||
Tango Therapeutics, Inc.(b)(c) | 1,776 | 13,498 | ||
Travere Therapeutics, Inc.(b)(c) | 1,324 | 8,315 | ||
Twist Bioscience Corp.(b)(c) | 1,004 | 24,146 | ||
Ultragenyx Pharmaceutical, Inc.(b)(c) | 1,434 | 55,711 | ||
uniQure N.V. (Netherlands)(b) | 845 | 5,729 | ||
United Therapeutics Corp.(b) | 820 | 196,800 | ||
UroGen Pharma Ltd.(b) | 534 | 7,043 | ||
Vanda Pharmaceuticals, Inc.(b) | 1,013 | 3,768 | ||
Vaxcyte, Inc.(b)(c) | 1,640 | 84,903 | ||
Veracyte, Inc.(b)(c) | 1,270 | 32,512 | ||
Vertex Pharmaceuticals, Inc.(b) | 4,124 | 1,463,236 | ||
Verve Therapeutics, Inc.(b)(c) | 1,121 | 12,645 | ||
Vir Biotechnology, Inc.(b)(c) | 2,339 | 22,197 | ||
Xencor, Inc.(b) | 1,058 | 19,404 | ||
Xenon Pharmaceuticals, Inc. (Canada)(b) | 1,123 | 41,079 | ||
Zai Lab Ltd., ADR (China)(b)(c) | 932 | 25,434 | ||
Zentalis Pharmaceuticals, Inc.(b) | 1,238 | 13,927 | ||
| 13,644,816 | ||||
| Health Care Equipment & Supplies-0.15% | ||||
Cue Health, Inc.(b) | 2,587 | 900 | ||
Novocure Ltd.(b)(c) | 1,868 | 22,921 | ||
| 23,821 | ||||
| Health Care Providers & Services-0.46% | ||||
23andMe Holding Co., Class A(b) | 5,312 | 4,571 | ||
Castle Biosciences, Inc.(b) | 468 | 9,355 | ||
Guardant Health, Inc.(b)(c) | 2,056 | 51,750 | ||
PetIQ, Inc.(b)(c) | 513 | 8,936 | ||
| 74,612 | ||||
| Life Sciences Tools & Services-3.26% | ||||
AbCellera Biologics, Inc. (Canada)(b) | 5,049 | 23,781 | ||
Adaptive Biotechnologies Corp.(b)(c) | 2,515 | 11,016 | ||
Codexis, Inc.(b) | 1,176 | 2,775 | ||
Illumina, Inc.(b) | 2,766 | 281,993 | ||
Maravai LifeSciences Holdings, Inc., Class A(b) | 2,297 | 11,715 | ||
MaxCyte, Inc.(b) | 1,821 | 8,650 | ||
Medpace Holdings, Inc.(b) | 534 | 144,564 | ||
NanoString Technologies, Inc.(b) | 801 | 398 | ||
Nautilus Biotechnology, Inc.(b) | 2,204 | 6,061 | ||
Pacific Biosciences of California, Inc.(b)(c) | 4,385 | 37,185 | ||
Quantum-Si, Inc.(b)(c) | 2,093 | 3,370 | ||
| 531,508 | ||||
| Pharmaceuticals-12.45% | ||||
Aclaris Therapeutics, Inc.(b) | 1,247 | 1,091 | ||
Amphastar Pharmaceuticals, Inc.(b)(c) | 854 | 48,097 | ||
Amylyx Pharmaceuticals, Inc.(b) | 1,175 | 16,638 | ||
ANI Pharmaceuticals, Inc.(b) | 354 | 17,633 | ||
Arvinas, Inc.(b)(c) | 937 | 20,586 | ||
AstraZeneca PLC, ADR (United Kingdom) | 10,178 | 657,397 | ||
ATAI Life Sciences N.V. (Germany)(b)(c) | 2,947 | 3,065 | ||
Atea Pharmaceuticals, Inc.(b)(c) | 1,467 | 4,386 | ||
Avadel Pharmaceuticals PLC, ADR(b)(c) | 1,556 | 17,956 | ||
Axsome Therapeutics, Inc.(b) | 825 | 55,646 | ||
Cara Therapeutics, Inc.(b) | 911 | 881 | ||
Collegium Pharmaceutical, Inc.(b)(c) | 605 | 15,506 | ||
Cymabay Therapeutics, Inc.(b)(c) | 1,931 | 36,940 | ||
Edgewise Therapeutics, Inc.(b)(c) | 1,105 | 6,718 | ||
Esperion Therapeutics, Inc.(b)(c) | 1,803 | 2,398 | ||
Evolus, Inc.(b) | 990 | 9,375 | ||
Fulcrum Therapeutics, Inc.(b) | 1,097 | 5,266 | ||
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
November 30, 2023
(Unaudited)
| Shares | Value | |||
| Pharmaceuticals-(continued) | ||||
Harmony Biosciences Holdings, Inc.(b)(c) | 1,050 | $30,513 | ||
Harrow, Inc.(b)(c) | 612 | 5,649 | ||
Hutchmed China Ltd., ADR (China)(b) | 543 | 10,469 | ||
Innoviva, Inc.(b)(c) | 1,141 | 15,803 | ||
Intra-Cellular Therapies, Inc.(b) | 1,679 | 103,040 | ||
Jazz Pharmaceuticals PLC(b)(c) | 1,104 | 130,526 | ||
Ligand Pharmaceuticals, Inc.(b)(c) | 303 | 17,668 | ||
Marinus Pharmaceuticals, Inc.(b)(c) | 877 | 5,902 | ||
Nektar Therapeutics(b) | 3,204 | 1,570 | ||
NGM Biopharmaceuticals, Inc.(b) | 1,394 | 1,041 | ||
Ocular Therapeutix, Inc.(b)(c) | 1,409 | 3,494 | ||
Omeros Corp.(b)(c) | 1,059 | 2,319 | ||
Optinose, Inc.(b)(c) | 1,891 | 2,364 | ||
Pacira BioSciences, Inc.(b)(c) | 809 | 22,070 | ||
Phathom Pharmaceuticals, Inc.(b)(c) | 986 | 6,892 | ||
Phibro Animal Health Corp., Class A | 359 | 3,443 | ||
Pliant Therapeutics, Inc.(b)(c) | 1,050 | 14,584 | ||
Revance Therapeutics, Inc.(b)(c) | 1,545 | 10,460 | ||
Royalty Pharma PLC, Class A | 7,841 | 212,256 | ||
Sanofi S.A., ADR | 4,927 | 230,337 | ||
SIGA Technologies, Inc.(c) | 1,234 | 6,701 | ||
Supernus Pharmaceuticals, Inc.(b)(c) | 955 | 26,024 | ||
Tarsus Pharmaceuticals, Inc.(b)(c) | 564 | 9,323 | ||
Terns Pharmaceuticals, Inc.(b)(c) | 1,080 | 4,806 | ||
Theravance Biopharma, Inc.(b)(c) | 927 | 9,715 | ||
Ventyx Biosciences, Inc.(b) | 1,029 | 2,223 | ||
| Shares | Value | |||
| Pharmaceuticals-(continued) | ||||
Verona Pharma PLC, ADR (United Kingdom)(b)(c) | 1,173 | $15,859 | ||
Viatris, Inc. | 20,964 | 192,450 | ||
WaVe Life Sciences Ltd.(b) | 1,721 | 9,138 | ||
Xeris Biopharma Holdings, Inc.(b) | 2,433 | 4,525 | ||
| 2,030,743 | ||||
TOTAL INVESTMENTS IN SECURITIES (excluding investments purchased with cash collateral from securities on loan)-99.97% (Cost $22,131,457) | 16,305,500 | |||
| Investments Purchased with Cash Collateral from Securities on Loan | ||||
| Money Market Funds-28.53% | ||||
Invesco Private Government Fund, 5.32%(e)(f)(g) | 1,303,326 | 1,303,326 | ||
Invesco Private Prime Fund, 5.55%(e)(f)(g) | 3,349,323 | 3,350,663 | ||
Total Investments Purchased with Cash Collateral from Securities on Loan (Cost $4,653,573) | 4,653,989 | |||
TOTAL INVESTMENTS IN SECURITIES-128.50% (Cost $26,785,030) | 20,959,489 | |||
OTHER ASSETS LESS LIABILITIES-(28.50)% | (4,648,430) | |||
NET ASSETS-100.00% | $16,311,059 | |||
| Investment Abbreviations: | |
| ADR | -American Depositary Receipt |
| Rts. | -Rights |
| Notes to Schedule of Investments: | |
| (a) | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s. |
| (b) | Non-income producing security. |
| (c) | All or a portion of this security was out on loan at November 30, 2023. |
| (d) | Security valued using significant unobservable inputs (Level 3). See Note 1. |
| (e) | Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2023. |
| Value August 31, 2023 | Purchases at Cost | Proceeds from Sales | Change in Unrealized Appreciation | Realized Gain | Value November 30, 2023 | Dividend Income | |||||||
| Investments in Affiliated Money Market Funds: | |||||||||||||
| Invesco Government & Agency Portfolio, Institutional Class | $- | $40,118 | $(40,118) | $- | $- | $- | $24 | ||||||
| Investments Purchased with Cash Collateral from Securities on Loan: | |||||||||||||
| Invesco Private Government Fund | 856,499 | 4,218,700 | (3,771,873) | - | - | 1,303,326 | 14,183* | ||||||
| Invesco Private Prime Fund | 2,202,426 | 7,138,159 | (5,991,108) | 416 | 770 | 3,350,663 | 37,184* | ||||||
| Total | $3,058,925 | $11,396,977 | $(9,803,099) | $416 | $770 | $4,653,989 | $51,391 |
| * | Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any. |
| (f) | The rate shown is the 7-day SEC standardized yield as of November 30, 2023. |
| (g) | The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return of the securities loaned. |
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
November 30, 2023
(Unaudited)
The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco PHLX Semiconductor ETF (SOXQ)
November 30, 2023
(Unaudited)
| Shares | Value | |||
| Common Stocks & Other Equity Interests-99.94% | ||||
| Electronic Equipment, Instruments & Components-0.43% | ||||
Coherent Corp.(b) | 18,786 | $691,137 | ||
| Semiconductors & Semiconductor Equipment-99.51% | ||||
Advanced Micro Devices, Inc.(b) | 119,855 | 14,521,632 | ||
Allegro MicroSystems, Inc. (Japan)(b) | 24,037 | 654,287 | ||
Amkor Technology, Inc. | 30,724 | 865,495 | ||
Analog Devices, Inc. | 34,819 | 6,385,108 | ||
Applied Materials, Inc. | 41,507 | 6,216,918 | ||
ASML Holding N.V., New York Shares (Netherlands) | 9,602 | 6,565,464 | ||
Axcelis Technologies, Inc.(b) | 4,102 | 509,797 | ||
Broadcom, Inc. | 13,730 | 12,710,273 | ||
Entegris, Inc. | 18,746 | 1,957,082 | ||
GLOBALFOUNDRIES, Inc.(b)(c) | 68,452 | 3,675,188 | ||
Intel Corp. | 360,564 | 16,117,211 | ||
KLA Corp. | 12,612 | 6,868,747 | ||
Lam Research Corp. | 9,012 | 6,451,871 | ||
Lattice Semiconductor Corp.(b) | 17,229 | 1,008,758 | ||
Marvell Technology, Inc. | 108,050 | 6,021,626 | ||
Microchip Technology, Inc. | 68,023 | 5,675,839 | ||
Micron Technology, Inc. | 90,673 | 6,902,029 | ||
Monolithic Power Systems, Inc. | 5,973 | 3,277,505 | ||
NVIDIA Corp. | 25,679 | 12,010,068 | ||
NXP Semiconductors N.V. (China) | 30,832 | 6,292,195 | ||
ON Semiconductor Corp.(b) | 53,927 | 3,846,613 | ||
Qorvo, Inc.(b) | 12,233 | 1,180,485 | ||
QUALCOMM, Inc. | 55,266 | 7,132,077 | ||
Rambus, Inc.(b) | 13,649 | 923,628 | ||
| Shares | Value | |||
| Semiconductors & Semiconductor Equipment-(continued) | ||||
Skyworks Solutions, Inc. | 19,915 | $1,930,361 | ||
Taiwan Semiconductor Manufacturing Co. Ltd., ADR (Taiwan) | 67,779 | 6,595,574 | ||
Teradyne, Inc. | 19,244 | 1,774,874 | ||
Texas Instruments, Inc. | 75,417 | 11,516,930 | ||
Wolfspeed, Inc.(b)(c) | 15,650 | 576,859 | ||
| 160,164,494 | ||||
TOTAL INVESTMENTS IN SECURITIES (excluding investments purchased with cash collateral from securities on loan)-99.94% (Cost $145,191,090) | 160,855,631 | |||
| Investments Purchased with Cash Collateral from Securities on Loan | ||||
| Money Market Funds-2.37% | ||||
Invesco Private Government Fund, 5.32%(d)(e)(f) | 1,067,826 | 1,067,826 | ||
Invesco Private Prime Fund, 5.55%(d)(e)(f) | 2,744,025 | 2,745,123 | ||
Total Investments Purchased with Cash Collateral from Securities on Loan (Cost $3,812,537) | 3,812,949 | |||
TOTAL INVESTMENTS IN SECURITIES-102.31% (Cost $149,003,627) | 164,668,580 | |||
OTHER ASSETS LESS LIABILITIES-(2.31)% | (3,716,871) | |||
NET ASSETS-100.00% | $160,951,709 | |||
| Investment Abbreviations: | |
| ADR | -American Depositary Receipt |
| Notes to Schedule of Investments: | |
| (a) | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s. |
| (b) | Non-income producing security. |
| (c) | All or a portion of this security was out on loan at November 30, 2023. |
| (d) | Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2023. |
| Value August 31, 2023 | Purchases at Cost | Proceeds from Sales | Change in Unrealized Appreciation | Realized Gain | Value November 30, 2023 | Dividend Income | |||||||
| Investments in Affiliated Money Market Funds: | |||||||||||||
| Invesco Government & Agency Portfolio, Institutional Class | $- | $530,489 | $(530,489) | $- | $- | $- | $346 | ||||||
| Investments Purchased with Cash Collateral from Securities on Loan: | |||||||||||||
| Invesco Private Government Fund | 1,040,517 | 5,552,825 | (5,525,516) | - | - | 1,067,826 | 11,576* | ||||||
| Invesco Private Prime Fund | 2,675,615 | 8,710,955 | (8,642,247) | 576 | 224 | 2,745,123 | 28,954* | ||||||
| Total | $3,716,132 | $14,794,269 | $(14,698,252) | $576 | $224 | $3,812,949 | $40,876 |
| * | Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any. |
| (e) | The rate shown is the 7-day SEC standardized yield as of November 30, 2023. |
| (f) | The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return of the securities loaned. |
See accompanying notes which are an integral part of this schedule.
Invesco PHLX Semiconductor ETF (SOXQ)—(continued)
November 30, 2023
(Unaudited)
The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco Solar ETF (TAN)
November 30, 2023
(Unaudited)
| Shares | Value | |||
| Common Stocks & Other Equity Interests-99.96% | ||||
| Building Products-0.32% | ||||
Triumph New Energy Co. Ltd., H Shares (China)(b)(c) | 7,632,304 | $4,172,687 | ||
| Chemicals-3.01% | ||||
Hanwha Solutions Corp. (South Korea)(b) | 1,515,603 | 39,236,632 | ||
| Construction & Engineering-0.26% | ||||
Emeren Group Ltd., ADR (China)(b)(c) | 1,411,191 | 3,415,082 | ||
| Electrical Equipment-15.07% | ||||
Array Technologies, Inc.(b)(c) | 3,496,759 | 54,094,862 | ||
Shoals Technologies Group, Inc., Class A(b)(c) | 3,917,948 | 54,263,580 | ||
Soltec Power Holdings S.A. (Spain)(b)(c) | 1,085,218 | 3,583,031 | ||
SunPower Corp.(b)(c) | 2,539,103 | 10,537,277 | ||
Sunrun, Inc.(b)(c) | 5,714,491 | 73,716,934 | ||
| 196,195,684 | ||||
| Independent Power and Renewable Electricity Producers-23.57% | ||||
Altus Power, Inc.(b)(c) | 1,079,446 | 5,397,230 | ||
Atlantica Sustainable Infrastructure PLC (Spain) | 875,607 | 16,654,045 | ||
Clearway Energy, Inc., Class C | 1,083,310 | 27,050,251 | ||
Doral Group Renewable Energy Resources Ltd. (Israel)(b)(c) | 2,642,663 | 3,945,438 | ||
Encavis AG (Germany)(b)(c) | 3,132,070 | 46,681,720 | ||
Energix-Renewable Energies Ltd. (Israel)(c) | 3,587,074 | 11,365,826 | ||
Enlight Renewable Energy Ltd. (Israel)(b)(c) | 1,513,692 | 26,188,126 | ||
Grenergy Renovables S.A. (Spain)(b)(c) | 432,449 | 13,796,755 | ||
Neoen S.A. (France)(d) | 896,547 | 27,409,801 | ||
OY Nofar Energy Ltd. (Israel)(b)(c) | 490,000 | 11,166,805 | ||
ReNew Energy Global PLC, Class A (India)(b)(c) | 1,286,866 | 8,287,417 | ||
RENOVA, Inc. (Japan)(b)(c) | 691,483 | 4,934,654 | ||
Scatec ASA (South Africa)(b)(c)(d) | 1,721,274 | 11,441,838 | ||
Solaria Energia y Medio Ambiente S.A. (Spain)(b)(c) | 2,056,255 | 38,511,060 | ||
Sunnova Energy International, Inc.(b)(c) | 2,722,545 | 31,581,522 | ||
West Holdings Corp. (Japan)(c) | 593,917 | 12,454,038 | ||
Xinyi Energy Holdings Ltd. (China)(c) | 59,110,652 | 9,914,466 | ||
| 306,780,992 | ||||
| Mortgage REITs-4.47% | ||||
Hannon Armstrong Sustainable Infrastructure Capital, Inc.(c) | 2,402,355 | 58,161,015 | ||
| Shares | Value | |||
| Semiconductors & Semiconductor Equipment-53.26% | ||||
Canadian Solar, Inc. (Canada)(b)(c) | 1,384,040 | $29,106,361 | ||
Daqo New Energy Corp., ADR (China)(b)(c) | 1,525,349 | 36,089,757 | ||
Enphase Energy, Inc.(b)(c) | 1,320,301 | 133,376,807 | ||
First Solar, Inc.(b)(c) | 866,429 | 136,705,167 | ||
Flat Glass Group Co. Ltd., H Shares (China)(c) | 10,876,251 | 17,880,371 | ||
GCL Technology Holdings Ltd. (China)(c) | 455,496,989 | 60,652,839 | ||
JinkoSolar Holding Co. Ltd., ADR (China)(c) | 1,198,413 | 37,630,168 | ||
Maxeon Solar Technologies Ltd.(b)(c) | 888,167 | 3,668,130 | ||
Meyer Burger Technology AG (Switzerland)(b)(c) | 89,834,460 | 21,116,858 | ||
Motech Industries, Inc. (Taiwan) | 10,331,000 | 9,309,144 | ||
SMA Solar Technology AG (Germany)(b)(c) | 465,966 | 28,293,331 | ||
SolarEdge Technologies, Inc.(b)(c) | 1,066,434 | 84,653,531 | ||
TSEC Corp. (Taiwan) | 14,272,000 | 13,477,081 | ||
United Renewable Energy Co. Ltd. (Taiwan) | 39,594,458 | 18,757,938 | ||
Xinyi Solar Holdings Ltd. (China) | 108,872,021 | 62,588,553 | ||
| 693,306,036 | ||||
TOTAL INVESTMENTS IN SECURITIES (excluding investments purchased with cash collateral from securities on loan)-99.96% (Cost $2,376,220,462) | 1,301,268,128 | |||
| Investments Purchased with Cash Collateral from Securities on Loan | ||||
| Money Market Funds-32.83% | ||||
Invesco Private Government Fund, 5.32%(e)(f)(g) | 119,465,754 | 119,465,754 | ||
Invesco Private Prime Fund, 5.55%(e)(f)(g) | 307,810,673 | 307,933,797 | ||
Total Investments Purchased with Cash Collateral from Securities on Loan (Cost $427,327,453) | 427,399,551 | |||
TOTAL INVESTMENTS IN SECURITIES-132.79% (Cost $2,803,547,915) | 1,728,667,679 | |||
OTHER ASSETS LESS LIABILITIES-(32.79)% | (426,857,738) | |||
NET ASSETS-100.00% | $1,301,809,941 | |||
See accompanying notes which are an integral part of this schedule.
Invesco Solar ETF (TAN)—(continued)
November 30, 2023
(Unaudited)
| Investment Abbreviations: | |
| ADR | -American Depositary Receipt |
| REIT | -Real Estate Investment Trust |
| Notes to Schedule of Investments: | |
| (a) | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s. |
| (b) | Non-income producing security. |
| (c) | All or a portion of this security was out on loan at November 30, 2023. |
| (d) | Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be resold pursuant to an exemption from registration under the 1933 Act, typically to qualified institutional buyers. The aggregate value of these securities at November 30, 2023 was $38,851,639, which represented 2.98% of the Fund’s Net Assets. |
| (e) | Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2023. |
| Value August 31, 2023 | Purchases at Cost | Proceeds from Sales | Change in Unrealized Appreciation | Realized Gain | Value November 30, 2023 | Dividend Income | |||||||
| Investments in Affiliated Money Market Funds: | |||||||||||||
| Invesco Government & Agency Portfolio, Institutional Class | $- | $2,628,779 | $(2,628,779) | $- | $- | $- | $378 | ||||||
| Investments Purchased with Cash Collateral from Securities on Loan: | |||||||||||||
| Invesco Private Government Fund | 130,829,433 | 146,691,331 | (158,055,010) | - | - | 119,465,754 | 1,571,033* | ||||||
| Invesco Private Prime Fund | 335,608,224 | 323,237,663 | (351,026,426) | 64,029 | 50,307 | 307,933,797 | 4,224,441* | ||||||
| Total | $466,437,657 | $472,557,773 | $(511,710,215) | $64,029 | $50,307 | $427,399,551 | $5,795,852 |
| * | Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any. |
| (f) | The rate shown is the 7-day SEC standardized yield as of November 30, 2023. |
| (g) | The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return of the securities loaned. |
| This Fund has holdings greater than 10% of net assets in the following country: | |
| China | 17.85% |
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Notes to Quarterly Schedules of Portfolio Holdings
November 30, 2023
(Unaudited)
NOTE 1—Additional Valuation Information
Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment’s assigned level:
Level 1 — Prices are determined using quoted prices in an active market for identical assets.
Level 2 — Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others.
Level 3 — Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Capital Management LLC’s assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.
The following is a summary of the tiered valuation input levels, as of November 30, 2023. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.
| Level 1 | Level 2 | Level 3 | Total | ||||
| Invesco Nasdaq Biotechnology ETF | |||||||
| Investments in Securities | |||||||
| Common Stocks & Other Equity Interests | $16,305,500 | $- | $0 | $16,305,500 | |||
| Money Market Funds | - | 4,653,989 | - | 4,653,989 | |||
| Total Investments | $16,305,500 | $4,653,989 | $0 | $20,959,489 | |||
| Invesco PHLX Semiconductor ETF | |||||||
| Investments in Securities | |||||||
| Common Stocks & Other Equity Interests | $160,855,631 | $- | $- | $160,855,631 | |||
| Money Market Funds | - | 3,812,949 | - | 3,812,949 | |||
| Total Investments | $160,855,631 | $3,812,949 | $- | $164,668,580 | |||
| Invesco Solar ETF | |||||||
| Investments in Securities | |||||||
| Common Stocks & Other Equity Interests | $1,301,268,128 | $- | $- | $1,301,268,128 | |||
| Money Market Funds | - | 427,399,551 | - | 427,399,551 | |||
| Total Investments | $1,301,268,128 | $427,399,551 | $- | $1,728,667,679 |